Institut de Cancérologie du Gard
- Address
- Rue du Pr Henri Pujol, 30000 Nîmes, France
Institut de Cancérologie du Gard
The Institut de Cancérologie du Gard is a comprehensive cancer research center conducting innovative clinical trials across multiple solid tumor malignancies. The institute demonstrates particular expertise in precision oncology and immunotherapy-based treatments, focusing on personalized therapeutic approaches guided by molecular profiling and biomarker assessment.
- Non-small cell lung cancer (NSCLC) including oligometastatic disease and early-stage resected tumors with molecular risk stratification
- Genitourinary cancers: metastatic renal cell carcinoma with molecular subgroup-directed therapy and non-seminomatous germ-cell tumors
- HER2-positive metastatic breast cancer with ctDNA-guided treatment de-escalation strategies
The center's research portfolio emphasizes novel treatment paradigms including local ablative therapies combined with immunotherapy for oligometastatic disease, early tumor marker kinetics for prognostic assessment, and circulating tumor DNA monitoring for therapeutic decision-making. Their trials investigate both treatment intensification in high-risk populations and de-escalation strategies in patients with favorable molecular profiles, reflecting a commitment to optimizing the balance between efficacy and quality of life across the cancer treatment spectrum.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 23 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Institut Gustave Roussy2active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Institut Gustave Roussy2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 980 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Institut de Cancérologie du Gard
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Adjuvant Chemotherapy with Paclitaxel, Cisplatin, and Carboplatin in High-Risk Stage I/IIA Non-Squamous NSCLC Post-Resection | Intergroupe Francophone De Cancerologie Thoracique, Razor Genomics Inc. | Phase III | Not Recruiting | Nov 2020 | — |
IMP list
lock Showing 1 of 23 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 3 | Unknown | 2020-11-03 | 2025-03-06 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.